FOPE seeks CDSCO clarification on pharmacovigilance obligations under revised Schedule M
The Federation of Pharma Entrepreneurs (FOPE) has sought clarifications from the Central Drugs Standard Control Organization…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
FOPE
Industry calls Union Budget 2026 a defining moment for India’s biopharma future
Industry stakeholders view the Union Budget 2026 as a pivotal inflection point in India’s life sciences journey. With the launch…
Session 22 of FOPE, PharmaState Academy’s PULSE Program drives compliance excellence in OSD…
The event began with a keynote address by Milan Patel, MD, Troikaa Pharmaceuticals, followed by an expert educator session by…
Session 21 of FOPE, PharmaState Academy’s PULSE Program, advances excellence in manufacture of APIs…
The keynote address was given by Namit Joshi, Chairman, Pharmexcil, followed by the expert educator session by Dr Jitender…
FOPE, PharmaState Academy’s 16th PULSE Session held on Oral Liquids manufacturing under Revised…
The session opened with a keynote address by Dr Viranchi Shah, followed by an education segment led by Abhijit S. Kulkarni, VP CQA…
Session 14 of FOPE & PharmaState Academy’s PULSE Program explores investigations & CAPA…
The session attracted over 250 attendees, reinforcing the PULSE series' role as a key learning platform for industry professionals
FOPE, PharmaState Academy, complete one year of the PULSE program
Session 23 focused on Manufacturing under Loan License or Contract in light of the Revised Schedule M Guidelines
FOPE & PharmaState Academy conducts session 17 on gap analysis and implementation plan for…
A structured and well-documented Gap Analysis is essential for identifying deficiencies, strengthening compliance, and ensuring…
FOPE and PharmaState Academy host session 13 of the PULSE series
The session focused on materials, reference Standards and vendor qualification under revised schedule M
FOPE & PharmaState Academy host Session 12 of the PULSE series
The session delivered comprehensive and precise insights on complaints and product recall under revised schedule M guidelines